These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 23378461)
1. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. Barra L; Bykerk V; Pope JE; Haraoui BP; Hitchon CA; Thorne JC; Keystone EC; Boire G; J Rheumatol; 2013 Aug; 40(8):1259-67. PubMed ID: 23378461 [TBL] [Abstract][Full Text] [Related]
2. Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative. de Punder YM; Hendrikx J; den Broeder AA; Valls Pascual E; van Riel PL; Fransen J J Rheumatol; 2013 Aug; 40(8):1268-74. PubMed ID: 23729803 [TBL] [Abstract][Full Text] [Related]
3. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort. Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE; J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342 [TBL] [Abstract][Full Text] [Related]
4. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. Barra L; Pope JE; Orav JE; Boire G; Haraoui B; Hitchon C; Keystone EC; Thorne JC; Tin D; Bykerk VP; J Rheumatol; 2014 Dec; 41(12):2361-9. PubMed ID: 25274884 [TBL] [Abstract][Full Text] [Related]
5. Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study. Mjaavatten MD; van der Heijde DM; Uhlig T; Haugen AJ; Nygaard H; Bjørneboe O; Kvien TK J Rheumatol; 2011 Nov; 38(11):2336-41. PubMed ID: 21965645 [TBL] [Abstract][Full Text] [Related]
6. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316 [TBL] [Abstract][Full Text] [Related]
7. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308 [TBL] [Abstract][Full Text] [Related]
8. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. Hitchon CA; Chandad F; Ferucci ED; Willemze A; Ioan-Facsinay A; van der Woude D; Markland J; Robinson D; Elias B; Newkirk M; Toes RM; Huizinga TW; El-Gabalawy HS J Rheumatol; 2010 Jun; 37(6):1105-12. PubMed ID: 20436074 [TBL] [Abstract][Full Text] [Related]
9. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966 [TBL] [Abstract][Full Text] [Related]
10. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829 [TBL] [Abstract][Full Text] [Related]
11. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044 [TBL] [Abstract][Full Text] [Related]
12. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Abdel-Nasser AM; Mahmoud MH; El Mansoury TM; Osman AM Scand J Rheumatol; 2008; 37(5):329-36. PubMed ID: 18666028 [TBL] [Abstract][Full Text] [Related]
13. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872 [TBL] [Abstract][Full Text] [Related]
14. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353 [TBL] [Abstract][Full Text] [Related]
15. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Hecht C; Englbrecht M; Rech J; Schmidt S; Araujo E; Engelke K; Finzel S; Schett G Ann Rheum Dis; 2015 Dec; 74(12):2151-6. PubMed ID: 25115448 [TBL] [Abstract][Full Text] [Related]
16. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion. Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216 [TBL] [Abstract][Full Text] [Related]
17. Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment. Wevers-de Boer KV; Heimans L; Visser K; Schouffoer AA; Molenaar ET; van Groenendael JH; Peeters AJ; Speyer I; Collée G; Huizinga TW; Allaart CF Rheumatology (Oxford); 2015 Aug; 54(8):1380-4. PubMed ID: 25687553 [TBL] [Abstract][Full Text] [Related]
18. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. van den Broek M; Dirven L; Klarenbeek NB; Molenaar TH; Han KH; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF Ann Rheum Dis; 2012 Feb; 71(2):245-8. PubMed ID: 22110122 [TBL] [Abstract][Full Text] [Related]
19. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. Castrejón I; Dougados M; Combe B; Fautrel B; Guillemin F; Pincus T J Rheumatol; 2016 Jul; 43(7):1285-91. PubMed ID: 27084913 [TBL] [Abstract][Full Text] [Related]
20. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]